Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect of chemotherapy
that is frequently experienced by patients receiving treatment for cancer. CIPN is caused by …

Cancer patients frequently develop chemotherapy-induced peripheral neuropathy (CIPN), a
painful and long-lasting disorder with profound somatosensory deficits. There are no …

Platinum‐induced peripheral neurotoxicity (PIPN) is a common side effect of platinum‐
based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin …

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and
potentially permanent side effect of cancer treatment. For the management of OIPN, accurate …

Background Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and
difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN …

Chemotherapy‐induced peripheral neurotoxicity (CIPN) is a major toxicity of cancer
treatment, leading to dose reduction and premature treatment cessation, potentially affecting …

Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common
toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and …